You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Prevalence analysis of OX40-positive cell populations in solid tumors
  1. James Ziai1,
  2. Gretchen Frantz1,
  3. Liping Zhang2,
  4. Cleopatra Kozlowski1,
  5. Houston Gilbert1,
  6. Jacquelyn Smith2,
  7. Marcin Kowanetz1,
  8. Jeong M Kim1 and
  9. Mahrukh Huseni1
  1. Aff1 grid.418158.10000000405344718Genentech, Inc. South San Francisco CA USA
  2. Aff2 grid.418158.10000000405344718Ventana Medical Systems, Inc. Tucson AZ USA

https://doi.org/10.1186/2051-1426-3-S2-P113

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Increased numbers of OX40+ T cells within the primary tumor of colorectal cancer (CRC) patients has been associated with improved survival. Similarly, OX40 expression in sentinel lymph nodes is inversely associated with tumor grade and clinical stage in melanoma patients. However, the prevalence of OX40+ tumor-associated lymphocytes remains underreported in many human solid tumor types. In this study, we report prevalence of OX40 by chromogenic immunohistochemistry in melanoma, colorectal, bladder, renal cell (RCC), triple-negative breast (TNBC), non-small cell lung (NCSCLC) and ovarian cancers and its association with available clinical parameters.

    Methods

    Tumor-associated OX40+ cells in melanoma (n=40), bladder (n=51), CRC (n=40), NSCLC (n=40), TNBC (n=45), ovarian (n=40) and RCC (n=42) patient samples including primary site and a subset of matched metastases have been stained for OX40 using a DAB-based chromogenic immunohistochemistry assay. Stained sections have been independently scored for OX40+ lymphocyte area percentage by two pathologists and a subset will be digitally imaged and analyzed. Image analysis includes OX40+ lymphocyte enumeration and area calculation within pathologist-defined regions of interest (ROI) to include the tumor and surrounding stroma. OX40 prevalence (OX40-positive cells/mm2 and % OX40+ cell area) were compared with patient age, clinical parameters, and outcome, where available, to determine potential associations.

    Results

    Results to be reported include a.) pathologist scoring of OX40+ cell prevalence b.) image analysis of OX40+ cell number and area percentage in a subset of indications c.) concordance between image analysis and pathologists' scores d.) OX40 prevalence by tumor type e.) OX40 prevalence and association with clinical features, where available, and statistical significance.

    Conclusions

    Prevalence of OX40 expression and association with clinical features are first reported in some solid tumor types.